Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

[31] Activation of this pathway results in the phosphorylation of MAPK, which then phosphorylates other factors and kinases, ultimately regulating cell survival, proliferation, and differentiation.

Researchers have discovered how a particular protein affects the growth and spread of colon cancer in humans. The study not ...

FIGURE 3. Targeting adhesion molecules in melanoma anoikis resistance. A range of integrins, as well as N-cadherin, and their downstream signalling pathways, including FAK (green), Mitogen-Activated ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Over 50% of melanomas harbor activating V600E mutations in Braf gene (BRAF V600E), an oncogene known to be critical for the proliferation and survival of melanoma cells through activation of the ...

In malignant melanoma, extracellular stimulus signals are transmitted ... regulation of tumor formation by participating in the EMT, Hippo, AKT, MAPK, and other related signaling pathways. In multiple ...